10
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T11773 | KRAS inhibitor-6 | Ras | |
KRAS inhibitor-6 is a potent KRAS G12C inhibitor. | |||
T40281 | KRAS G12D inhibitor 6 | ||
KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D. | |||
T3725 | K-Ras(G12C) Inhibitor 6 | Raf | |
K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant that causes 100% modification of the protein when used at 10 μM for 24 hours in vitro. | |||
T12979 | BI-3406 | p38 MAPK , MAPK , Ras | |
BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity. | |||
T6878 | LJI308 | S6 Kinase | |
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. | |||
T63164 | KRAS inhibitor-13 | ||
KRAS inhibitor-13 (compound 5-6) is a potent inhibitor of KRAS G12C (IC50: 0.883 μM). KRAS inhibitor-13 has a p-ERK inhibitory effect in MIA PaCA-2, A549 cells with IC50 values of 5.9 and >100 μM respectively. KRAS inhib... | |||
T62751 | KRAS inhibitor-12 | ||
KRAS inhibitor-12 (compound 6-1) is a potent inhibitor of KRAS G12C (IC50: 0.537 μM). KRAS inhibitor-12 exhibits p-ERK inhibition in MIA PaCA-2, A549 cells with IC50 values of 1.3, 3.7 μM respectively. KRAS inhibitor-12 ... | |||
T79800 | Pan-KRAS-IN-2 | Ras | |
Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D, G12C, G12V, G12S, G12A, Q61H), while showing significantly... | |||
T72356 | KRAS G12C inhibitor 56 | ||
KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research. | |||
T36676 | Rineterkib hydrochloride | ||
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly relat... |